Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 4/20 | 0.44 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 13/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12241721 | 0.92 | IL2 (0.53) | IL2STIM1ORAI1ABL1ALDH1A1 | |
| SCHEMBL12241732 | 0.86 | IL2 (0.51) | IL2STIM1ORAI1ABL1 | |
| SCHEMBL12241722 | 0.85 | NPC1 (0.54) | IL2STIM1ORAI1ABL1ALDH1A1 | |
| SCHEMBL12156310 | 0.84 | IL2 (0.47) | IL2STIM1ORAI1ABL1ALDH1A1 | |
| SCHEMBL12241719 | 0.83 | NPC1 (0.50) | IL2STIM1ORAI1ABL1ALDH1A1 | |
| SCHEMBL12241729 | 0.82 | ABL1 (0.48) | STIM1ORAI1ABL1ALDH1A1CYP2C19 | |
| SCHEMBL12241727 | 0.80 | IL2 (0.54) | IL2STIM1ORAI1 | |
| SCHEMBL12155680 | 0.78 | STIM1 (0.47) | IL2STIM1ORAI1ABL1ALDH1A1 | |
| SCHEMBL12155836 | 0.78 | IL2 (0.53) | IL2STIM1ORAI1ABL1ALDH1A1 | |
| SCHEMBL16572573 | 0.78 | IL2 (0.46) | IL2STIM1ORAI1ABL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-2563776-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-8980629-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | IL2 3716/4885STIM1 17/4885ORAI1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.